NCT02455921View on ClinicalTrials.gov

Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

April 30, 2018

Conditions
Anesthesia; Functional
Interventions
DRUG

neostigmine - atropine

Efficacy, safety and effect on cognitive and behavioural function

DRUG

Sugammadex

Efficacy, safety and effect on cognitive and behavioural function

Trial Locations (1)

12462

2nd Department of Anesthesiology, Attikon University Hospital, Athens

All Listed Sponsors
lead

Attikon Hospital

OTHER

NCT02455921 - Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children | Biotech Hunter | Biotech Hunter